CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
| Bid date, 2023-01-24 | |
| Auction date | 2023-01-24 |
| Settlement date | 2023-01-25 |
| Maturity Date | 2023-02-01 |
| Nominal amount | 586 billion SEK |
| Interest rate | 2.50 % |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Bids are made to phone number | 08-696 69 70 |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 586 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 1 172 billion SEK |
| Expected excess liquidity at full allotment | 586 billion SEK |
Stockholm, 2023-01-24
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Completion of capital reduction in Spar Nord Bank A/S26.4.2024 08:45:00 CEST | Press release
Company announcement no. 28 As stated in company announcement no. 22, it was decided at Spar Nord Bank A/S’ ordinary general meeting on 19 March 2024 to reduce the company’s share capital by DKK 27,645,950 nominal value divided into 2,764,595 shares of DKK 10 through the cancellation of treasury shares. The capital reduction was published via the Danish Business Authority’s IT system on 26 March 2024. The statutory notice period has expired with no claims received. The capital reduction has been finally registered with the Danish Business Authority on 25 April 2024. After the capital reduction, the share capital of Spar Nord Bank A/S amounts to DKK 1,177,020,310 nominal value divided into shares of DKK 10 each. Pursuant to section 32 of the Danish Capital Markets Act, we hereby announce that the company’s total share capital and total number of voting rights amount to: Share capital (nominal value): DKK 1,177,020,310 Number of voting rights: 117,702,031 Please direct any questions rega
Gennemførelse af kapitalnedsættelse i Spar Nord Bank A/S26.4.2024 08:45:00 CEST | pressemeddelelse
Selskabsmeddelelse nr. 28 Som oplyst i selskabsmeddelelse nr. 22 blev det på Spar Nord Bank A/S’ ordinære generalforsamling den 19. marts 2024 besluttet at nedsætte selskabets aktiekapital med nominelt DKK 27.645.950 fordelt i 2.764.595 aktier à DKK 10 ved annullation af egne aktier. Offentliggørelse af kapitalnedsættelsen har fundet sted i Erhvervsstyrelsens it-system den 26. marts 2024. Proklamafristen er udløbet uden indsigelser. Kapitalnedsættelsen er endeligt registreret den 25. april 2024 hos Erhvervsstyrelsen. Efter kapitalnedsættelsen udgør aktiekapitalen i Spar Nord Bank A/S nominelt DKK 1.177.020.310 fordelt i aktier à DKK 10. I henhold til §32 i lov om kapitalmarkeder oplyses det hermed, at selskabets samlede aktiekapital og samlede antal stemmerettigheder er opgjort til: Aktiekapital (nominelt): DKK 1.177.020.310 Antal stemmerettigheder: 117.702.031 Spørgsmål i forbindelse med denne meddelelse kan rettes til undertegnede på 96 34 42 36. Venlig hilsen Rune Brandt Børglum IR-
Adevinta (ASA) publishes its 2023 Annual Report26.4.2024 08:30:00 CEST | Press release
Oslo, 26 April 2024 – Adevinta ASA today released its 2023 Annual Report, available here. A printed copy may be obtained free of charge upon written request to: ir@adevinta.com. Reflecting on 2023, Antoine Jouteau, CEO, said: “Over the past year, we have made significant progress on redesigning our operating model, verticalising our organisation in line with our Growing At Scale strategy and successfully completing our portfolio optimisation. We have achieved strong financial and operational performance in 2023 and continued to deliver against our targets, despite the tough macroeconomic environment. Following the divestment of our Hungarian classifieds business, our portfolio is now centred around our core European markets of France, Germany, Spain, Italy and Benelux, complemented by Canada and our joint ventures. We are delivering significant growth in our Mobility, Re-Commerce and Real Estate & Emerging verticals, substantiating our focus in these areas. By putting technology and pr
PCI Biotech Holding ASA - Annual Report 202326.4.2024 08:08:19 CEST | Press release
Oslo, Norway, April 26, 2024. The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2023. Please find the report attached, as well as the report according to the European Single Electronic Format (ESEF). The Annual Report 2023 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO, rs@pcibiotech.no, Mobile: +47 940 05 757 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments 2023 Annual Report PCI Biotech Holding ASApcibiotechholdingasa-2023-12-31-en
Delårsrapport för januari – mars 202426.4.2024 08:00:00 CEST | Pressemelding
STOCKHOLM – den 26 april 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) publicerar idag sin delårsrapport för januari – mars 2024. Den fulla rapporten är tillgänglig på bolagets hemsida. ”Det har varit en stark inledning på 2024 där utvecklingen inom respektive portföljbolag löper enligt plan. Trots att vi haft ett motigt marknadsklimat har våra portföljbolag outtröttligt fortsatt driva utvecklingen av framtidens behandlingar vidare för att de så snabbt som möjligt ska komma patienterna till gagn. Vi ser fram emot tilltagande medvind och fler framsteg under året”, säger Viktor Drvota, VD, Karolinska Development. Väsentliga händelser under första kvartalet Portföljbolaget OssDsign rapporterade positiva data från den kliniska studien TOP FUSION. Top-line-resultaten, som granskats av oberoende radiologer, visar en fusionsgrad på 93 procent 12 månader efter operation med det nya nanosyntetiska bengraftet OssDsign Catalyst (januari 2024).Portföljbolaget AnaCardio erhöll SEK 50 mil